Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2541)	10/5/2009 12:42:55 PM
From: Jibacoa	Respond to of 3722

CXM is up 16.15% on volume of 150,250 still below its ADV. On Thursday it announced plans to report on preliminary safety and efficacy data from its Matrix PII2b Excellarate clinical study. Based on guidance from its independent clinical data management company which is currently completing the statistical analysis of all data for the Matrix clinical trial,CXM expects to receive the locked unblinded data set and be in position to announce preliminary results on or before Oct 14 It plans to hold a webcast to review the clinical data, details of which will be provided with announcement of the Matrix clinical results.<g> That announcement appeared to come at the right time to try to lift the stock from its recent dip to the $1.29 level.<g> bigcharts.marketwatch.com The stock nearest resistance is now at $1.65 before it can test again the $2 level.<g> bigcharts.marketwatch.com Although it has been trimming its loss for 4Qs, the revenues have been lower in the last 3Qs.<g> Bernard